Coronary artery disease, hypercholesterolemia
Conditions
Interventions
Lipid management treatment flow with the goal of "
an LDL-C reduction of >
= 50% from baseline and LDL-C <
55 mg/dL"
Sponsors
Yokohama City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients aged 18 years or older at the time of enrollment (2) Patients diagnosed with coronary artery disease (3) Patients diagnosed with hypercholesterolemia (hypercholesterolemia: LDL-C >= 140 mg/dL, or taking cholesterol-lowering medication) (4) Patients who provide written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: (1) Patients who are expected to have difficulty visiting the hospital (2) Patients whose prognosis is expected to be within one year (3) Patients with statin hypersensitivity, ezetimibe hypersensitivity, or evolocumab hypersensitivity (4) Patients with the following conditions considered to have impaired liver metabolic function (acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer, jaundice) (5) Patients who are pregnant, may be pregnant, or wish to become pregnant during treatment (6) Patients receiving cyclosporine, glecaprevir, or pibrentasvir (7) Patients with a history of treatment with evolocumab or inclisiran (8) Patients who have participated in clinical trials of drugs or medical devices at the same time as this study or within 30 days prior to enrollment in this study (9) Patients who are otherwise deemed inappropriate as subjects by a physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achievement rate of LDL-C < 70 mg/dL at 1 year | — |
Countries
Japan
Contacts
Public ContactMasaomi Gohbara
Yokohama City University Medical Center Division of Cardiology
Outcome results
None listed